Pfizer begins early-stage study of oral drug to combat coronavirus
The drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SA, said the antiviral candidate showed potent activity against SARS-CoV-2, the virus that causes COVID-19, in lab studies.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Coronavirus | COVID-19 | Germany Health | Pfizer | Pharmaceuticals | SARS | Study | Vaccines